Role of Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma

Bin-Yan Zhong; Zhi-Cheng Jin; Jian-Jian Chen; Hai-Dong Zhu; Xiao-Li Zhu

doi:10.14218/JCTH.2022.00293

Role of Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma

J Clin Transl Hepatol. 2023 Apr 28;11(2):480-489. doi: 10.14218/JCTH.2022.00293. Epub 2022 Sep 6.

Authors

Bin-Yan Zhong¹, Zhi-Cheng Jin², Jian-Jian Chen², Hai-Dong Zhu², Xiao-Li Zhu¹

Affiliations

¹ Department of Interventional Radiology, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
² Center of Interventional Radiology & Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu, China.

Abstract

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. According to the Barcelona Clinic Liver Cancer (BCLC) staging system, transarterial chemoembolization (TACE) is the first-line recommendation for intermediate-stage HCC. In real-world clinical practice, TACE also plays an important role in early- and advanced-stage HCC. This review article by the experts from Chinese Liver Cancer Clinical Study Alliance (CHANCE) summarizes the available clinical evidence pertaining to the current application of TACE in patients with early-, intermediate-, and advanced-stage HCC. In addition, combination of TACE with other treatment modalities, especially immunotherapy, is reviewed.

Keywords: Hepatocellular carcinoma; Immunotherapy; TACE.

Publication types

Review